{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:42:29Z","timestamp":1790808149138,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_204470\/1"],"award-info":[{"award-number":["310030_204470\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["CRSII5_180323"],"award-info":[{"award-number":["CRSII5_180323"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030L_197952\/1"],"award-info":[{"award-number":["310030L_197952\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Swiss Cancer League","doi-asserted-by":"publisher","award":["KFS-4962-02-2020"],"award-info":[{"award-number":["KFS-4962-02-2020"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) for which both genetic and environmental risk factors have been identified. The strongest synergy among them exists between the MHC class II haplotype and infection with the Epstein Barr virus (EBV), especially symptomatic primary EBV infection (infectious mononucleosis) and elevated EBV-specific antibodies. In this review, we will summarize the epidemiological evidence that EBV infection is a prerequisite for MS development, describe altered EBV specific immune responses in MS patients, and speculate about possible pathogenic mechanisms for the synergy between EBV infection and the MS-associated MHC class II haplotype. We will also discuss how at least one of these mechanisms might explain the recent success of B cell-depleting therapies for MS. While a better mechanistic understanding of the role of EBV infection and its immune control during MS pathogenesis is required and calls for the development of innovative experimental systems to test the proposed mechanisms, therapies targeting EBV-infected B cells are already starting to be explored in MS patients.<\/jats:p>","DOI":"10.3390\/microorganisms9112191","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:22:02Z","timestamp":1634862122000},"page":"2191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Epstein Barr Virus Exploits Genetic Susceptibility to Increase Multiple Sclerosis Risk"],"prefix":"10.3390","volume":"9","author":[{"given":"Fabienne","family":"L\u00e4derach","sequence":"first","affiliation":[{"name":"Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-1940","authenticated-orcid":false,"given":"Christian","family":"M\u00fcnz","sequence":"additional","affiliation":[{"name":"Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.121.5.761","article-title":"Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt\u2019s lymphoma","volume":"121","author":"Epstein","year":"1964","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Rickinson","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in the oncogenesis of the Epstein Barr virus","volume":"17","year":"2019","journal-title":"Nat. Rev. Micobiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2012-08-450775","article-title":"Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205","volume":"121","author":"Leung","year":"2013","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1074-7613(00)00049-2","article-title":"The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell","volume":"13","author":"Babcock","year":"2000","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1073\/pnas.2237267100","article-title":"Demonstration of the Burkitt\u2019s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo","volume":"101","author":"Hochberg","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","article-title":"EBV persistence in memory B cells in vivo","volume":"9","author":"Babcock","year":"1998","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coviro.2016.09.001","article-title":"Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?","volume":"20","author":"Totonchy","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/femsre\/fuy044","article-title":"Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses","volume":"43","author":"Damania","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/imr.12791","article-title":"Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases","volume":"291","author":"Latour","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.2019000928","article-title":"Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0301-0082(95)80008-V","article-title":"Migrant studies in multiple sclerosis","volume":"47","author":"Gale","year":"1995","journal-title":"Prog. Neurobiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/archneur.1966.00470150012002","article-title":"Risk of multiple sclerosis related to age at immigration to Israel","volume":"15","author":"Alter","year":"1966","journal-title":"Arch. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/01.wnl.0000247663.40297.2d","article-title":"Multiple sclerosis and the hygiene hypothesis","volume":"67","author":"Fleming","year":"2006","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/jnnp.29.1.60","article-title":"Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation","volume":"29","author":"Leibowitz","year":"1966","journal-title":"J. Neurol. Neurosurg Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dowd, J.B., Palermo, T., Brite, J., McDade, T.W., and Aiello, A. (2013). Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6\u201319, 2003\u20132010. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064921"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students","volume":"207","author":"Balfour","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.20820","article-title":"Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis","volume":"59","author":"Thacker","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.291.15.1875","article-title":"Epstein-Barr virus in pediatric multiple sclerosis","volume":"291","author":"Alotaibi","year":"2004","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1212\/01.wnl.0000247665.94088.8d","article-title":"High seroprevalence of Epstein-Barr virus in children with multiple sclerosis","volume":"67","author":"Pohl","year":"2006","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI111388","article-title":"Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis","volume":"73","author":"Tosato","year":"1984","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.131.4.1797","article-title":"Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus","volume":"131","author":"Tsokos","year":"1983","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4049\/jimmunol.172.2.1287","article-title":"Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus","volume":"172","author":"Kang","year":"2004","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awl067","article-title":"Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis","volume":"129","author":"Edwards","year":"2006","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4049\/jimmunol.181.2.991","article-title":"Increased frequency of EBV specific effector memory CD8+ T cells is associated with higher viral load in rheumatoid arthritis","volume":"181","author":"Frey","year":"2008","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.4049\/jimmunol.174.11.6599","article-title":"EBV and systemic lupus erythematosus: A new perspective","volume":"174","author":"Gross","year":"2005","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.21682","article-title":"An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus","volume":"54","author":"McClain","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archneur.63.6.noc50328","article-title":"Epstein-Barr virus and multiple sclerosis: Evidence of association from a prospective study with long-term follow-up","volume":"63","author":"DeLorenze","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.293.20.2496","article-title":"Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis","volume":"293","author":"Levin","year":"2005","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/eji.200324144","article-title":"Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients","volume":"33","author":"Colombo","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.4049\/jimmunol.164.5.2782","article-title":"Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients","volume":"164","author":"Colombo","year":"2000","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1212\/WNL.42.9.1798","article-title":"Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein","volume":"42","author":"Bray","year":"1992","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1172\/JCI200523661","article-title":"Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis","volume":"115","author":"Cepok","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jneuroim.2010.04.007","article-title":"Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis","volume":"225","author":"Nociti","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2016.08.016","article-title":"The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins","volume":"299","author":"Dooley","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jneuroim.2017.07.013","article-title":"Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins","volume":"310","author":"Lindsey","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","article-title":"Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein","volume":"80","author":"Wucherpfennig","year":"1995","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-\u03b3 and IL-2","volume":"205","author":"Jelcic","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2249.2003.02114.x","article-title":"Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis","volume":"132","author":"Hollsberg","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/brain\/awn108","article-title":"Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis","volume":"131","author":"Jilek","year":"2008","journal-title":"Brain"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Angelini, D.F., Serafini, B., Piras, E., Severa, M., Coccia, E.M., Rosicarelli, B., Ruggieri, S., Gasperini, C., Buttari, F., and Centonze, D. (2013). Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003220"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1352458508100037","article-title":"Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis","volume":"15","author":"Nielsen","year":"2009","journal-title":"Mult. Scler."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/eji.202048655","article-title":"Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15","volume":"51","author":"Zdimerova","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","article-title":"HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis","volume":"183","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1352458508092353","article-title":"EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: A case-control study","volume":"14","author":"Sundstrom","year":"2008","journal-title":"Mult. Scler."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.08.004","article-title":"Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis","volume":"215","author":"Sundstrom","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/375798a0","article-title":"The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis","volume":"375","author":"Bajramovic","year":"1995","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u2014From targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41598-019-55850-z","article-title":"The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis","volume":"10","author":"Afrasiabi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity","volume":"50","author":"Harley","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103572","DOI":"10.1016\/j.ebiom.2021.103572","article-title":"The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype","volume":"71","author":"Keane","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.0713607","article-title":"Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition","volume":"182","author":"Brooks","year":"2009","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial","volume":"63","author":"Calabresi","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: Targeting B cells in multiple sclerosis","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41467-019-14118-w","article-title":"Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis","volume":"11","author":"Schafflick","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1073\/pnas.2008523117","article-title":"A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis","volume":"117","author":"Ramesh","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12974-017-1049-5","article-title":"Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis","volume":"15","author":"Veroni","year":"2018","journal-title":"J. Neuroinflammation."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1212\/NXI.0000000000000466","article-title":"Molecular signature of Epstein-Barr virus infection in MS brain lesions","volume":"5","author":"Moreno","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1093\/brain\/awp296","article-title":"Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis","volume":"133","author":"Peferoen","year":"2010","journal-title":"Brain"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awp200","article-title":"Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain","volume":"132","author":"Willis","year":"2009","journal-title":"Brain"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gasser, O., Bihl, F.K., Wolbers, M., Loggi, E., Steffen, I., Hirsch, H.H., Gunthard, H.F., Walker, B.D., Brander, C., and Battegay, M. (2007). HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040096"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood.2020009968","article-title":"Sorting biologic subtypes of primary CNS lymphoma","volume":"137","author":"Roschewski","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458514521888","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis","volume":"20","author":"Pender","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e124714","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"652811","DOI":"10.3389\/fneur.2021.652811","article-title":"Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein-Barr Virus-Specific T Cell Therapy","volume":"12","author":"Ioannides","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.tig.2021.04.012","article-title":"Multiple sclerosis: Doubling down on MHC","volume":"37","author":"Martin","year":"2021","journal-title":"Trends Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.molmed.2021.01.004","article-title":"Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26, 3 p:296-310, 2020)","volume":"27","author":"Pender","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41568-021-00396-4","article-title":"Removing global barriers to cervical cancer prevention and moving towards elimination","volume":"21","author":"Alfaro","year":"2021","journal-title":"Nat. Rev. Cancer."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI125364","article-title":"Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas","volume":"129","author":"Citterio","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"R\u00fchl, J., Leung, C.S., and M\u00fcnz, C. (2020). Vaccination against the Epstein-Barr virus. Cell Mol. Life Sci.","DOI":"10.1007\/s00018-020-03538-3"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: An important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","article-title":"Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy","volume":"72","author":"Smith","year":"2012","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A virus-like particle-based Epstein-Barr virus vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"van Zyl, D.G., Tsai, M.H., Shumilov, A., Schneidt, V., Poirey, R., Schlehe, B., Fluhr, H., Mautner, J., and Delecluse, H.J. (2018). Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007464"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/11\/2191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:19:46Z","timestamp":1760167186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/11\/2191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":93,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["microorganisms9112191"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms9112191","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}